Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients

M. Pierantozzi, A. Pietroiusti, G. Sancesario, G. Lunardi, E. Fedele, P. Giacomini, S. Frasca, A. Galante, M. G. Marciani, P. Stanzione

Research output: Contribution to journalArticlepeer-review

Abstract

We report that the area under the curve of L-dopa plasma concentration, following the administration of a single 250 mg L-dopa dose, is augmented after Helicobacter pylori (HP) eradication in six Parkinson's disease (PD) patients showing high IgG antibody titer against HP. A prolongation of L-dopa clinical benefit was also observed. We suggest that HP infection-activated gastric alterations may be responsible, at least in part, for the reported erratic efficacy of oral L-dopa therapy in some advanced PD patients. Given the high percentage of HP-positivity in the age cohorts including the largest prevalence of PD patients, we propose that HP eradication be recommended in all PD patients under L-dopa therapy.

Original languageEnglish
Pages (from-to)89-91
Number of pages3
JournalNeurological Sciences
Volume22
Issue number1
DOIs
Publication statusPublished - Feb 2001

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients'. Together they form a unique fingerprint.

Cite this